Examine Case 3: You will be asked to make three decisions concerning the diagnosis and treatment for this client. Be sure to consider co-morbid physical as well as mental factors that might impact the clients diagnosis and treatment.
At each Decision Point, stop to complete the following:
    Decision #1: Differential Diagnosis
o    Which Decision did you select?
o    Why did you select this Decision? Support your response with evidence and references to the Learning Resources.
o    What were you hoping to achieve by making this Decision? Support your response with evidence and references to the Learning Resources.
o    Explain any difference between what you expected to achieve with Decision #1 and the results of the Decision. Why were they different?
    Decision #2: Treatment Plan for Psychotherapy
o    Why did you select this Decision? Support your response with evidence and references to the Learning Resources.
o    What were you hoping to achieve by making this Decision? Support your response with evidence and references to the Learning Resources.
o    Explain any difference between what you expected to achieve with Decision #2 and the results of the Decision. Why were they different?
    Decision #3: Treatment Plan for Psychopharmacology
o    Why did you select this Decision? Support your response with evidence and references to the Learning Resources.
o    What were you hoping to achieve by making this Decision? Support your response with evidence and references to the Learning Resources.
o    Explain any difference between what you expected to achieve with Decision #3 and the results of the decision. Why were they different?
    Also include how ethical considerations might impact your treatment plan and communication with clients and their family.
    Include a clear and comprehensive purpose statement.
    Integrate 2 or more credible, up to date outside sources, in addition to 2-3 course resources to suppport point of view.
Case 3: Neurocognitive Disorders
Laureate Education (Producer). (2017a). A gentleman with a neurocognitive disorder [Multimedia file]. Baltimore, MD: Author.
Learning Resources:
Acadia Pharmaceuticals. (2017). Transform the treatment of Parkinsons disease psychosis with NUPLAZID. Retrieved from https://www.nuplazidhcp.com/?gclid=CIHS5auvwtMCFQkaaQodrU0FGQ
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC: Author.
Gabbard, G. O. (2014). Gabbards treatment of psychiatric disorders (5th ed.). Washington, DC: American Psychiatric Publications.
Hopkins, S. A., & Chan, D. (2016). Key emerging issues in frontotemporal dementia. Journal of Neurology, 263(2), 407413. doi:10.1007/s00415-015-7880-7
Sadock, B. J., Sadock, V. A., & Ruiz, P. (2014). Kaplan & Sadocks synopsis of psychiatry: Behavioral sciences/clinical psychiatry (11th ed.). Philadelphia, PA: Wolters Kluwer.
Stahl, S. M. (2014). Prescribers Guide: Stahls Essential Psychopharmacology (5th ed.). New York, NY: Cambridge University Press.